Charles River Laboratories International (NYSE:CRL) Price Target Raised to $375.00

Key Points

• Barclays raised its price target on Charles River Laboratories to $375 from $330 and maintained an overweight rating, implying about 18% upside from the stock’s then-current price.
• Charles River beat quarterly estimates, reporting adjusted EPS of $3.09 versus $2.97 expected and revenue of $982.7 million versus $960.4 million expected. However, revenue declined 2.2% year over year.
• Analyst views are mostly positive: MarketBeat listed a consensus “Moderate Buy” rating and an average target of $304.83, while Zacks Research downgraded the stock to Hold.

Charles River Laboratories International (NYSE:CRL - Get Free Report) had its target price increased by analysts at Barclays from $330.00 to $375.00 in a note issued to investors on Thursday, Benzinga reports. The firm currently has an "overweight" rating on the medical research company's stock. Barclays's price objective would suggest a potential upside of 18.24% from the company's current price.

A number of other research firms have also recently weighed in on CRL. Jefferies Financial Group raised their price objective on shares of Charles River Laboratories International from $305.00 to $340.00 and gave the stock a "buy" rating in a report on Monday, September 28th. TD Cowen upped their price objective on shares of Charles River Laboratories International from $300.00 to $325.00 and gave the company a "buy" rating in a research note on Friday, September 25th. Zacks Research lowered Charles River Laboratories International from a "strong-buy" rating to a "hold" rating in a report on Monday. Morgan Stanley lifted their target price on Charles River Laboratories International from $300.00 to $340.00 and gave the stock an "overweight" rating in a research report on Monday, October 12th. Finally, CLSA cut Charles River Laboratories International from an "outperform" rating to a "hold" rating and set a $219.00 target price for the company. in a research report on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Charles River Laboratories International presently has a consensus rating of "Moderate Buy" and an average price target of $304.83.

Charles River Laboratories International Stock Down 2.8%

Charles River Laboratories International stock traded down $9.15 during mid-day trading on Thursday, reaching $317.14. 843,172 shares of the company's stock were exchanged, compared to its average volume of 962,260. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.92. Charles River Laboratories International has a twelve month low of $146.20 and a twelve month high of $379.63. The company has a market cap of $15.14 billion, a P/E ratio of -65.72, a P/E/G ratio of 3.29 and a beta of 1.36. The company has a fifty day moving average of $304.55 and a 200-day moving average of $224.12.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, November 4th. The medical research company reported $3.09 EPS for the quarter, topping the consensus estimate of $2.97 by $0.12. The firm had revenue of $982.73 million during the quarter, compared to analysts' expectations of $960.36 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%. Charles River Laboratories International's revenue for the quarter was down 2.2% on a year-over-year basis. During the same period in the previous year, the firm posted $2.43 EPS. Sell-side analysts expect that Charles River Laboratories International will post 11.38 EPS for the current year.

Insider Activity

In other Charles River Laboratories International news, Director James C. Foster sold 24,042 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, October 22nd. The shares were sold at an average price of $350.00, for a total value of $8,414,700.00. Following the completion of the sale, the director directly owned 31,596 shares of the company's stock, valued at approximately $11,058,600. The trade was a 43.21% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nancy C. Andrews sold 573 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $285.24, for a total value of $163,442.52. Following the transaction, the director owned 1,438 shares in the company, valued at $410,175.12. This trade represents a 28.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 102,299 shares of company stock valued at $31,050,863 over the last quarter. 1.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Charles River Laboratories International

Several hedge funds and other institutional investors have recently made changes to their positions in CRL. Lido Advisors LLC bought a new stake in Charles River Laboratories International during the third quarter worth about $1,205,000. New York Life Investment Management LLC raised its stake in shares of Charles River Laboratories International by 371.3% in the third quarter. New York Life Investment Management LLC now owns 61,506 shares of the medical research company's stock valued at $18,145,000 after acquiring an additional 48,455 shares during the last quarter. AlphaCore Capital LLC raised its holdings in shares of Charles River Laboratories International by 222.4% in the third quarter. AlphaCore Capital LLC now owns 5,184 shares of the medical research company's stock valued at $1,529,000 after buying an additional 3,576 shares during the last quarter. Retirement Systems of Alabama grew its holdings in Charles River Laboratories International by 1,246.1% during the 3rd quarter. Retirement Systems of Alabama now owns 136,211 shares of the medical research company's stock worth $40,184,000 after acquiring an additional 126,092 shares during the last quarter. Finally, Fulcrum Asset Management LLP bought a new position in shares of Charles River Laboratories International in the third quarter worth about $85,000. Institutional investors and hedge funds own 98.91% of the company's stock.

Charles River Laboratories International News Roundup

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: CRL reported Q3 adjusted earnings of $3.09 per share, above analysts’ roughly $2.97–$2.98 estimates and up from $2.43 a year earlier. Revenue of $982.7 million also exceeded the $960.4 million consensus. Charles River Q3 Earnings & Revenues Top Estimates, Stock Rises
• Positive Sentiment: Organic growth and margin expansion helped drive results, and the company raised its 2026 outlook—an encouraging sign for its expected near-term performance. Charles River Laboratories Lifts Annual Outlook
• Negative Sentiment: Despite beating estimates, revenue declined 2.2% year over year, a sign that underlying sales trends remain a potential concern. Charles River Laboratories Announces Third-Quarter 2026 Results
• Negative Sentiment: Zacks Research lowered its rating on CRL from “strong-buy” to “hold,” which could weigh on sentiment despite the earnings beat and improved outlook. Zacks Research stock recommendations

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.